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ABSTRACT 
Stochastic Process Model has many applications in analysis of 
longitudinal biodemographic data. Such data contain various 
physiological variables (sometimes known as covariates). It also 
can potentially contain genetic information available for all or a 
part of participants. Taking advantage from both genetic and non-
genetic information can provide future insights into a broad range 
of processes describing aging-related changes in the organism. In 
this paper, we implemented a multi-dimensional Genetic 
Stochastic Process Model (GenSPM) in newly developed software 
tool, R-package stpm, which allows researchers performing such 
kind of analysis. 
Keywords 
Stochastic process model; allostatic load; quadratic hazard; 
longitudinal data; life tables; risk factors; aging-related 
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1. INTRODUCTION 
Developing aging-related diseases is mediated by thousands of 
biological and physiological variables, which are undergo 
environmental and social factors, individual behavioral patterns. 
Various studies show involvement of genetic component in 
developing aging-related diseases and its potential effect on 
longevity [1-3]. Longitudinal study is probably the most important 
component of study and evaluating contribution of physiological 
variables to decline of the health/well-being status and a lifespan. 
Longitudinal data can also contain genetic information of 
individuals participated to the study. In such data genetic 
component represents genetic information in form of a genetic 
marker describing a particular allele. However, such longitudinal 
data often comes from different studies and often is incomplete, 
meaning that only a part of individuals are genotyped. 
Incompleteness in longitudinal data may arise from several 
factors, for example: (a) not all individuals are genotyped since 
some of those who initially participated in a longitudinal study 
have already deceased or left the study; (b) difficulty in gathering 
genetic information, which may arise from various reasons, for 
example, cost of genotyping or, perhaps, an individual refused to 
provide genetic samples; (c) this also can happen due to loss of 
some parts of experimental data during data preparation or 
storage. 
Incomplete data often confounds the analysis leading to potential 
misleading results. Such cases are typical in epidemiological 
studies when a measure of a certain variable (covariate) is difficult 
to obtain for majority of participants. The common approach is to 
divide participants into two subgroups: the larger subgroup, which 
does not carry information of a particular variable, which is 
difficult to collect; and a smaller subgroup in which measures of 
such variable are presented. This is so-called two-stage analysis. 
Methods for analyzing such kind of data are well developed for 
regression models [4,5]. These methods employ information from 
the first subgroup (named the “first stage”) and combine it with 
data from the second subgroup (or “second stage”) in order to 
better estimate regression parameters. Using such methods can 
potentially improve precision of estimates in comparison to 
analysis based on the smaller group exclusively. 
A common way of evaluating effects of genetic variability on 
health/well-being/survival condition is to estimate respective 
hazards (can be mortality rate) separately for carriers and non-
carriers of particular allele (genotype). In absence of information 
of physical factors and processes affecting a hazard rate, an 
evaluation of a genetic effect is well developed in GWAS. 
Genetic data combined with longitudinal data can potentially, 
provide an opportunity of studying indirect genetic effects with 
trajectories of physiological variables, mediated by age, which, in 
turn, can model processes in organism not directly measured in 
pure longitudinal data. Therefore there is a need for special 
statistical methods and software tools that perform such kind of 
analysis. 
The Stochastic Process Model (SPM) [6, 8, 9], and its extension, a 
genetic SPM (“GenSPM”) [10], developed to deal with 
longitudinal data with presence of genetic information, and 
represents an important step toward joint analysis of longitudinal 
data (with corresponding genetic information) by considering 
together genetic- and non-genetic groups (genotyped and non-
genotyped groups of participants). In this work, we (i) further 
extend the conception of GenSPM to a multi-dimensional case 
and (ii) provide a corresponding software tool: an R-package 
‘stpm’, that implements GenSPM methodology. The stpm was 
verified thought extensive simulation and validation studies. This 
paper is also an attempt to partially close the problem of limited 
usage of the SPM methodology, arising from the lack of user-
friendly software, documentation and examples, and promote and 
popularize it to academic and clinical audience. 
 
2. METHODS 
Originally, the Stochastic Process Model (SPM) was developed 
several decades ago at Duke University [6] and represents a 
general framework for modeling joint evolution of repeatedly 
measured variables (e.g., physiological or biological measures, 
also called covariates) and time-to-event outcomes observed in 
longitudinal studies. In other words, SPM links the stochastic 
dynamics of variables to the probabilities of end points (e.g., 
death or system failure). The dynamics of the stochastic variables 
is modeled by N-dimensional stochastic process (where N 
represents a number of physiological variables used in the study) 
and has two components: the first component, which is related to 
the basic regularities of the age-related physiological changes and 
the second is a stochastic component which integrates the effects 
of external and internal perturbations of the dynamics of the 
physiological covariates. 
In SPM methodology, the morbidity/mortality risk is presented as 
the quadratic hazard function, also known as U- or J- shaped 
hazard function [12-17], which is justified empirically based on 
many epidemiological observations for various biomarkers (see, 
e.g., [12,17]). The minimum of a hazard function, a paraboloid in 
the multivariable case, is a point (or domain) in the variable state 
space, which corresponds to the optimal system status (e.g., the 
"normal" health status) with the minimal hazard at a specific time 
(age). 
In general, the SPM can be applied in the same manner as the Cox 
model with time-dependent covariates [7] (delete this reference). 
However, the advantage of the SPM methodology is that it takes 
into account the stochastic dynamics of variables assuming that 
the respective process satisfies a certain stochastic model, which 
better describes the reality in many applications. Finally, SPM 
allows projection/prediction of individual physiological 
trajectories, which opens possibilities for targeted research such as 
personalized prognoses. 
GenSPM, presented in 2009 by Arbeev at al [10] (and further 
elaborated in 2014 “Joint analysis of longitudinal and time to 
event data”, 2015 “Latent class and genetic stochastic processs 
model” (JSM) by Arbeev), further elaborates the basic stochastic 
process model conception by introducing a categorical variable, Z, 
which may be a specific value of a genetic marker or, in general, 
any categorical variable. Currently, Z has two gradations: 0 or 1 in 
a genetic group of interest, assuming that P(Z=1) = p, p ∈ [0, 1], 
were p is the proportion of carriers and non-carriers of an allele in 
a population. Example of longitudinal data with genetic 
component Z is provided in Table 1. In the previous study, the 
GenSPM model was verified on a single physiological variable 
but its behavior if more than one variable used is not known. The 
general concern is that using a single variable may not be enough 
for performing comprehensive hypotheses evaluations.  
In this work we conducted corresponding simulation studies to 
evaluate second GenSPM dimension using simulation studies with 
two physiological variables by providing its validation and testing 
using one and two physiological covariates.  
We also present a corresponding software tool, an R-package 
‘stpm’, freely available for download from CRAN: https://cran.r-
project.org/web/packages/stpm/ which is the first publicly 
available software, implementing the general SPM and its 
extension, GenSPM, allowing researchers analyzing and making 
predictions from longitudinal data with genetic component. 
 
2.1 Description of algorithms 
The block-scheme of the SPM is presented in Figure 1. In the 
specification of the SPM described in 2007 paper by Yashin and 
colleagues [8] the stochastic differential equation describing the 
age dynamics of a physiological variable (a dynamic component 
of the model) is: 
 
dY(t) = a(Z, t)(Y(t) – f1(Z, t))dt + b(Z, t)dW(t), Y(t = t0). (1) 
 
Here in this equation, Y(t) is a k × 1 matrix, where k is a number 
of covariates, which is a model dimension) describing the value of 
a physiological variable at a time (e.g. age) t. f1(Z,t) is a k × 1 
matrix that corresponds to the long-term average value of the 
stochastic process Y(t), which describes a trajectory of individual 
variable influenced by different factors represented by a random 
Wiener process W(t). The negative feedback coefficient a(Z,t) (k 
× k matrix) characterizes the rate at which the stochastic process 
goes to its mean. In research on aging and well-being, f1(Z,t) 
represents the average allostatic trajectory and a(t) in this case 
represents the adaptive capacity of the organism. Coefficient 
b(Z,t) (k × 1 matrix) characterizes a strength of the random 
disturbances from Wiener process W(t). All of these parameters 
depend on Z (a genetic marker having values 1 or 0). 
The following function μ(t,Y(t)) represents a hazard rate: 
μ(t,Y(t)) = μ0(t) + (Y(t) - f(Z, t))*Q(Z, t)(Y(t) - f(Z, t)), (2) 
In this equation: μ0(t) is the baseline hazard, which represents a 
risk when Y(t) follows its optimal trajectory; f(t) (k × 1 matrix) 
represents the optimal trajectory that minimizes the risk and Q(Z, 
t) (k x k matrix) represents a sensitivity of risk function to 
deviation from the norm. In general, model coefficients a(Z, t), 
f1(Z, t), Q(Z, t), f(Z, t), b(Z, t) and μ0(t) are time(age)-dependent. 
For example, the coefficient a can be assumed as (i) -0.05 (a 
constant, time-independent, one-dimensional model) or (ii) a(t) = 
a0 + b0t (time-dependent), in which a0 and b0 are unknown 
parameters to be estimated. Presented model can handle, in 
Figure 1. Block-scheme of GenSPM. In this picture, part I is 
described by the equation (1) and part II is described by the 
equation 2 (morbidity/mortality risk). 
 
theory, any number of physiological variables, however using 
many variables may lead to extensive usage of computational 
resources. Symbol ‘*’ denotes transpose operation. 
In order to estimate coefficients a(Z, t), f1(Z, t), Q(Z, t), f(Z, t), 
b(Z, t) and μ0(t) which are the parameters of stochastic process, a 
method of maximizing likelihood is used (described in the next 
section). 
 
ID Status Age Age.next Z DBP DBP.next 
1 0 96.61 97.59 0 94.62 100.68 
1 0 97.59 98.67 0 100.68 100.59 
1 0 98.67 99.67 0 100.59 102.31 
1 1 99.67 100.70 0 102.31 NA 
2 0 64.78 65.78 1 81.77 80.62 
2 0 65.78 66.78 1 80.62 70.49 
2 0 66.78 67.68 1 70.49 69.20 
2 0 67.68 68.66 1 69.20 67.74 
… … … … … … … 
 
 
2.1.1 Likelihood function for genetic group 
The likelihood equations for genotyped (genetic) group were 
presented in [10] and is shown below: 
Lg = pN1g (0)(1− p)N0g (0) Lgi (1)
i=1
N1g (0)
∏ Lgi (0)
i=1
N0g (0)
∏    
In this equation, N1g(0)  and N0g(0)  are the numbers of 
individuals having Z=1 and 0 in the beginning of the study. The 
likelihood for i-th individual calculated as follows: 
 
Lgi (z) = µ i (z,τ i )δi exp − µ i (z, t)dt
t0i
τ i
∫
⎧
⎨
⎪
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Then the hazard rate can be estimated with the following 
equation: 
µ i (z, t) = µ0 (z, t)+ (mi (z, t)− f (z, t))*Q(z, t)(mi (z, t)− f (z, t))
+Tr(Q(z, t)γ i (z, t))
  
Functions m(z, t) and γ(z, t) are mean and variance of the 
conditional distribution P(Y(t) ≤ y | Z = z, T > t) that satisfy the 
following system of differential equations: 
dmi (z, t)
dt = a(z, t)(m
i (z, t)− f (z, t))
−2γ i (z, t)Q(z, t)(mi (z, t)− f (z, t))
 
dγ i (z, t)
dt = a(z, t)γ
i (z, t)−γ i (z, t)a(z, t)*+b(z, t)b(z, t)*
−2γ i (z, t)Q(z, t)γ i (z, t)*
  
 
These equations are then solved at the intervals between 
observation times [𝑡!! , 𝑡!! ), [𝑡!! , 𝑡!! ),…,[𝑡!! !,𝜏!), with initial 
conditions 𝑦!(𝑡!! ), …,𝑦!(𝑡!! !) and γz,0,0,..0 respectively. Therefore, 
trajectories for mi(z, t) and γi(z, t) are different for each individual 
and so estimates of the chances of death for each individual are 
different; 𝛿! is a censoring indicator for i-th individual (1 – death, 
0 - censored); 𝑡!! !is the last measurement of physiological variable 
before death/censoring at 𝜏! for i-th individual. 
2.1.2 Likelihood function for non-genetic group 
 
Assuming that the population of interest is heterogeneous, i.e. a 
mix of carriers and non-carries of particular allele or genotype, 
randomly selected from the data, we can write the following 
likelihood equation for non-genetic group [10]: 
Lng = (pLgi (1)+ (1− p)Lgi (0))
i=1
Nng (0)
∏  
here p is an expected proportion of carriers in a population; Nng(0) 
represents the number of individuals in the non-genetic group at a 
time (age) t0. Likelihoods Lgi (1)  and Lgi (0)  are calculated using 
equation (4) above. 
 
2.1.3 Joint analysis of genetic and non-genetic data 
In order to combine the data from genetic and non-genetic groups, 
we use the following joint likelihood: 
L = LgLng   
In this equation Lg  and Lng  are likelihoods computed from 
genetic and non-genetic groups. This joint likelihood is then 
maximized used some well-known optimization method (we used 
Nelder-Mead [18] or COBYLA [19] optimization methods other 
methods are available in the R-package stpm) and thereby 
parameter estimates are obtained. These estimates can be used to 
test the hypotheses on different respective parameters for carriers 
and non-carriers of particular genetic marker: differences between 
the general model with parameters do not depend on Z to the 
model with Z-dependent parameters. This, in turn, will show the 
presence of a genetic effect in respective component of the model. 
2.2 R-package stpm 
We developed an R-package “stpm” that comprises the SPM-
methodology. The package allows for estimating several versions 
of SPM currently available in the literature including discrete- 
[20] and continuous-time multidimensional models [8] and a one-
dimensional model with time-dependent parameters [9] and SPM 
with genetic component, described in this work. Also, the package 
provides routines for data preprocessing, simulation and 
projection of individual trajectories and hazard functions 
(microsimulations). The R-package stpm is available as open 
source software from the following link: https://cran.r-
project.org/web/packages/stpm/index.html. [Add functions how to 
run the analysis] 
The R-package stpm contains two following functions that 
basically objectify GenSPM methodology described in this article: 
(i) simdata_gen(…) 
(ii) spm_gen(…) 
The simdata_gen(…) is used for data simulation which may 
be useful in case of data absence and the spm_gen(…) provides 
Table 1. Example of longitudinal data with genetic component Z presented as a 
dichotomous value of some genetic marker (Z = 1 for carriers and 0 for non-
carriers). Here “ID” is a person’s identification number in a database; “Status” 
represents death (1) or censoring (0) of an individual at age “Age.next”; “DBP” 
is a physiological variable, which is diastolic blood pressure in this example. 
(8) 
(9) 
(3) 
(4) 
(6) 
(5) 
(7) 
Table 2. Description of the tests: Ng1 and Ng2 – numbers of individuals in 
the genetic group (two separate genetic groups simulated), Nng – number of 
individuals in the non-genetic group. There were 100 datasets simulated for 
each group. 
estimation of the parameters of the model described above. In the 
example below we show how to work with this function: 
library(stpm) 
#Data simulation: 
data <- simdata_gen(N=100, mode=’genetic’) 
head(data) 
#Estimation of parameters: 
pars <- spm_gen(gendat=data) 
pars 
 
Here we simulated a dataset containing N=100 genotyped 
individuals (using parameter mode=’genetic’) and then 
estimated all parameters for the one-dimensional model. 
In the next example we show joint analysis of two datasets: first 
dataset with genetic and second dataset with non-genetic 
component (on simulated data, as in previous example): 
library(stpm) 
# Data simulation for genetic and non-genetic group: 
data.genetic <- simdata_gen(N=100, mode='genetic') 
data.nongenetic <- simdata_gen(N=500, mode='nongenetic') 
#Estimation of parameters: 
pars <- spm_gen(gendat=data.genetic, nongendat = 
data.nongenetic, mode='combined') 
pars 
Here we use mode=’genetic’, which indicates that two 
datasets, one from genetic (or genotyped) group and second from 
non-genetic (not-genotyped) group. 
 
2.3 Verification strategies 
In order to verify the conception presented, and test the 
corresponding R-package ‘stpm’, we conducted simulation 
studies. Using the R-package stpm we performed simulations and 
then model parameter estimations for genetic groups and then we 
estimated parameters from combined data (genetic and non-
genetic groups). Specifically, we simulated the following datasets 
containing one and two variables: (i) 100 datasets for genetic 
group contained N=100 individuals; 100 datasets for genetic 
group of 1,000 of individuals; and 100 datasets for non-genetic 
group of 5,000 of individuals, with p = 0.25 in all cases (Test 1); 
(ii) the same strategy but we used two physiological variables 
instead of one (Test 2). Table 2 presents the summary of these 
datasets. Initial values of Y(t) are assumed normally distributed: 
N(f1(t0), σ02), where f1(t0) is the value of f1 in time t=t0 (t0 ∈[30, 
60], uniformly distributed). 
 
 
 
Test # # of  
covariates 
Ng1 Ng2 Nng Ng1+Nng 
1 1 100 1,000 5,000 100 + 5,000 
2 2 100 1,000 5,000 100 + 5,000 
 
3. RESULTS 
3.1 Test 1 
Table 3 contains results for Test 1. In this test we performed 
evaluation of model behavior for one physiological variable. For 
genetic group, parameter estimates, such as p, Q, f1 are getting 
close to their true values used in simulation as number of 
individuals in the cohort increases. Estimates obtained from 
combined data: genetic (100 of individuals) + non-genetic groups 
(5,000 of individuals) are very close to those parameters used in 
simulation. 
3.2 Test 2 
Table 4 shows results for Test 2 (two physiological variables 
used). Even with small number of individuals (100), parameter 
estimates are close to their true values. As in previous case, 
parameter estimates are close to the parameters used in data 
simulations. 
4. DISCUSSION 
Longitudinal data contain measurements of various physiological 
variables. Such data can also contain genetic information of 
subjects. Often only genetic information from such data is 
selected for study of specific problem, leaving untouched the rest 
of the data. Such analysis on abridged data can lead to misleading 
and unpredicted results therefore it must be extended to use data 
from a non-genetic subgroup as well. Combining results from 
different studies is another example of such problem. 
From the other side, analysis only of genetic component presented 
in longitudinal data may often not be enough since it does not 
offer an entire picture on aging-related changes in humans 
providing only an overview of genetic influence on such 
mechanisms. Stochastic Process Model and its extension, Genetic 
SPM (‘GenSPM’) allow researchers to utilize the entire potential 
of longitudinal data by evaluating dynamic mechanisms of 
changing physiological variables with time (age), allowing 
studying differences in genotype-specific hazards. Applying the 
Stochastic Process Model to analysis of longitudinal data 
uncovers influences of hidden components (adaptive capacity, 
allostatic load, resistance to stresses, physiological norm) of 
aging-related changes, which play important role in aging-related 
processes but cannot be measured directly with common statistical 
methods. This brings researchers to a new way of analyzing 
longitudinal data, however there are several concerns that should 
be taken into account before conducting such data analysis. 
The first concern is an assumption that the genetic group is a 
random sample from the entire cohort under study. In reality this 
may not be true because, for example, only people with some 
particular disease were genotyped or some of them refused 
participating to genotyping or already deceased. The methods that 
take this into account should be elaborated. 
Second concern is an assumption of specific forms of hazard risk 
function. In our approach we assume that the hazard rate 
(incidence rate related to changing physiological variable with 
age) has the form of U- or J- shape, which is biologically justified 
by empirical observations. In reality, the true form of such 
function is not known and since it is impossible to estimate it from 
the data, incorrectly assumed hazard may introduce additional 
bias. Additional investigations are needed in order to evaluate 
effects of different forms of hazard functions on results. 
We performed our studies and proposed a software tool for 
random variable Z with two gradations: 0 and 1. However, the 
GenSPM can be easily extended to three values: 0, 1 and 2 
corresponding to genotypes “aa”, “Aa” and “AA”. 
In this work we presented a first software implementation a multi-
dimensional genetic SPM, ‘GenSPM’ and corresponding software 
tool (an R-package ‘stpm’). Future work includes further 
improvements of the model, e.g. introducing three genetic 
markers and testing on higher number of variables. Clinical and 
academic researchers will benefit from using presented model and 
software. 
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N 
a11H a11L f11H f11L Q11H x 10-4 Q11L x 10-4 f1H b1H b1L 𝝁0H x 10-2 p 
100 
(genetic) 
-0.186  
[-0.241,  
-0.151] 
-0.192  
[-0.232,  
-0.156] 
41.7  
[36.8,  
46.2] 
47.8  
[41.3,  
56] 
0.55  
[0.466,  
0.65] 
0.343  
[0.262,  
0.439] 
40.9  
[35.9,  
45] 
4.98  
[4.48,  
5.49] 
3.97  
[3.44,  
4.47] 
0.27  
[0.223,  
0.337] 
0.26  
[0.206,  
0.307] 
1,000 
(genetic) 
-0.187  
[-0.239,  
-0.153] 
-0.183  
[-0.228,  
-0.153] 
42  
[36.2,  
47.4] 
47.3  
[41.4,  
54.4] 
0.551  
[0.467,  
0.649] 
0.337  
[0.271,  
0.433] 
40.9  
[37,  
44.6] 
4.97  
[4.51,  
5.44] 
3.95  
[3.39,  
4.42] 
0.259  
[0.214,  
0.302] 
0.258  
[0.216,  
0.301] 
100 + 5,000 
(combined) 
-0.183  
[-0.235,  
-0.151] 
-0.19  
[-0.235, 
 -0.157] 
43.4  
[38.6,  
49] 
45.3  
[40.3,  
49.7] 
0.562  
[0.475,  
0.661] 
0.353 
 [0.261,  
0.459] 
43.3  
[36.9,  
48.8] 
5  
[4.52,  
5.47] 
4.03  
[3.44,  
4.57] 
0.287  
[0.232,  
0.35] 
0.265  
[0.208,  
0.31] 
True 
-0.2 -0.2 40 45 5e-05 3e-05 40 5 4 0.25 0.25 
 
 N 
a22H a22L f12H f12L Q22H x 10-4 Q22L x 10-4 f2H b2H b2L 𝝁0L x 10-3 
 100 
(genetic) 
-0.187  
[-0.24,  
-0.153] 
-0.191  
[-0.231,  
-0.156] 
80.7  
[76.2,  
84.8] 
89.7  
[85.2,  
94.2] 
0.539  
[0.466,  
0.641] 
0.0319  
[0.263,  
0.388] 
81  
[76.6,  
84.9] 
7.03  
[6.5,  
7.52] 
5.97  
[5.51,  
6.45] 
0.342  
[0.271,  
0.414] 
 
 
1,000 
(genetic) 
-0.187  
[-0.234, 
 -0.153] 
-0.182  
[-0.227,  
-0.152] 
80  
[75.7,  
84.5] 
89.5  
[85.3,  
93.9] 
0.516  
[0.464,  
0.561] 
0.317  
[0.261,  
0.384] 
80.1  
[76.6,  
84.2] 
7.01  
[6.48,  
7.49] 
5.97  
[5.5,  
6.48] 
0.343  
[0.274,  
0.404] 
 
 
 
100 + 5,000 
(combined) 
-0.185  
[-0.24,  
-0.147] 
-0.19  
[-0.236,  
-0.157] 
82.4  
[76.1,  
88.6] 
90.5  
[85.6,  
94.7] 
0.541  
[0.458,  
0.637] 
0.341  
[0.253,  
0.461] 
82.7  
[76.7,  
87.9] 
7.03  
[6.5,  
7.49] 
6.01  
[5.52,  
6.49] 
0.362  
[0.27,  
0.454] 
 True 
-0.2 -0.2 80 90 5e-05 3e-05 80 7 6 0.33 
  
N aH aL f1H f1L QH x 10-4 
QL 
x 10-4 fH fL bH bL 
𝝁0H 
x 10-2 
𝝁0L 
x 10-3 p 
100 
(genetic) 
-0.202 
[-0.24, 
-0.169] 
-0.201 
[-0.221, 
-0.18] 
40 
[38.9, 
41.1] 
45 
[44.6, 
45.5] 
0.507 
[0.311, 
0.679] 
0.304 
[0.108, 
0.491] 
40.2 
[35.4, 
46.2] 
49.9 
[46.7, 
54.6] 
5 
[4.82, 
5.18] 
4 
[3.92, 
4.07] 
0.221 
[0.101, 
0.38] 
0.316 
[0.108, 
0.494] 
0.293 
[0.191, 
0.399] 
1,000 
(genetic) 
-0.198 
[-0.209, 
-0.187] 
-0.2 
[-0.206, 
-0.193] 
40 
[39.6, 
40.4] 
45 
[44.9, 
45.2] 
0.529 
[0.421, 
0.667] 
0.327 
[0.229, 
0.427] 
40.1 
[38.2, 
42.5] 
49.6 
[48.2, 
51.5] 
5 
[4.94, 
5.06] 
4 
[3.98, 
4.03] 
0.227 
[0.113, 
0.332] 
0.325 
[0.151, 
0.491] 
0.261 
[0.159, 
0.344] 
100 + 5,000 
(combined) 
-0.199 
[-0.205, 
-0.19] 
-0.199 
[-0.203, 
-0.196] 
40.1 
[39.7, 
40.3] 
45 
[44.9, 
45.1] 
0.533 
[0.427, 
0.635] 
0.322 
[0.226, 
0.429] 
40.7 
[39.2, 
42.2] 
49.6 
[48.3, 
51] 
4.99 
[4.94, 
5.04] 
4.01 
[3.99, 
4.02] 
0.242 
[0.144, 
0.344] 
0.351 
[0.173, 
0.457] 
0.252 
[0.228, 
0.276] 
True -0.2 -0.2 40 45 0.5 0.3 40 50 5 4 0.25 0.33 0.25 
 
Table 3. Results for one-dimensional simulation (one physiological variable), for two genetic and joint genetic and non-genetic groups. 
Values in brackets contain 95% confidence interval, lower and upper bound. True parameter values are those used in simulation. Here 
‘H’ and ‘L’ represents parameters when Z = 1 (H) and 0 (L). 
Table 4. Results for two-dimensional simulation (two physiological variables), for two genetic and joint genetic and non-genetic groups. Values in 
brackets contain confidence 95% interval, lower and upper bound. True parameter values are those used in simulation. For matrices a and Q only 
components on the main diagonal are shown. ‘H’ and ‘L’ represents parameters when Z = 1 (H) and 0 (L). 
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